H-1337 is under clinical development by D. Western Therapeutics Institute and currently in Phase II for Open-Angle Glaucoma. According to GlobalData, Phase II drugs for Open-Angle Glaucoma have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how H-1337’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
H-1337 overview
H-1337 (ALY-1337) is under development for the treatment of open-angle glaucoma (POAG), ocular hypertension and pulmonary hypertension. It acts by targeting LRRK2. It is administered through ophthalmic route as a solution.
D. Western Therapeutics Institute overview
D. Western Therapeutics Institute (DWTI) is a biotechnology company that discovers and develops new drugs. The company’s pipeline products include ripasudil hydrochloride hydrate targets for glaucoma and ocular hypertension and Fuchs endothelial corneal dystrophy; DWR-2206 for bullous keratopathy; DW-5LBT treats neuropathic pain; H-1337 for glaucoma and ocular hypertension; DW-1001 treats Ophthalmic Treatment Agent; DW-1002 targets ILM staining and ERM and PVR membrane staining, among others. DWTI is headquartered in Nishiki, Nagoya, Japan.
For a complete picture of H-1337’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
